Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

June 2nd 2024

Taletrectinib demonstrated high response rates and a tolerable safety profile in patients with ROS1-positive non–small cell lung cancer.

Virtual and In-Person Delivery of Palliative Care Confers Equivalent QOL Benefit in Advanced Lung Cancer

June 2nd 2024

The delivery of palliative care through telehealth vs in-person visits was equally beneficial for patients with advanced non–small cell lung cancer.

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation

June 2nd 2024

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo in limited-stage small cell lung cancer.

Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC

June 2nd 2024

Osimertinib after definitive chemoradiotherapy improved PFS vs placebo in locally advanced, EGFR-mutated non–small cell lung cancer.

Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

June 1st 2024

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Adagrasib Improves Survival, Responses in KRAS G12C+ Advanced NSCLC

June 1st 2024

Compared with standard-of-care chemotherapy, adagrasib significantly improved PFS and tumor responses in KRASG12C-mutated locally advanced or metastatic NSCLC.

Subcutaneous Amivantamab Shows Noninferior ORR vs IV Formulation in EGFR+ NSCLC

June 1st 2024

Subcutaneous amivantamab was displayed noninferiority in terms of ORR vs intravenous administration in EGFR-mutated non–small cell lung cancer.

Amivantamab Plus Lazertinib Improves PFS Irrespective of Risk in EGFR-Mutant NSCLC

June 1st 2024

Amivantamab plus lazertinib improved progression-free survival vs osimertinib as frontline therapy in patients with high-risk, EGFR-mutant advanced NSCLC.

Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur

June 1st 2024

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC

May 31st 2024

Christine Lovly, MD, PhD, shares data on BDTX-1535, a “masterkey” EGFR inhibitor targeting classical, non-classical, and the C797S resistance mutation in patients with EGFR mutant non-small cell lung cancer (NSCLC), from a presentation at AACR 2024.

First-Line Ivonescimab Improves PFS vs Pembrolizumab in PD-L1+ NSCLC in China

May 31st 2024

Ivonescimab monotherapy improved PFS vs pembrolizumab in the first-line treatment of PD-L1–positive NSCLC in China.

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC

May 31st 2024

Lorlatinib extended PFS and improved time to intracranial progression vs crizotinib in patients with ALK-positive non–small cell lung cancer.

Revisit Every OncLive On Air Episode From May 2024

May 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Key Takeaways in HER2-Mutated NSCLC

May 29th 2024

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

Treatment Considerations in HER2-Mutated NSCLC

May 29th 2024

Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.

AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC

May 29th 2024

The FDA granted fast track designation AFM24 plus atezolizumab for advanced EGFR wild-type non–small cell lung cancer.

FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy for Advanced Pleural Mesothelioma

May 29th 2024

The FDA granted priority review to an sBLA seeking the approval of pembrolizumab plus chemotherapy as frontline therapy in malignant pleural mesothelioma.

Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer

May 28th 2024

The expert panel underscores the critical importance of rapid diagnostic testing and identification of driver alterations to optimize patient outcomes, given the often-narrow therapeutic window for chemotherapy and targeted therapies.

NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing

May 28th 2024

Key opinion leaders examine the current National Comprehensive Cancer Network (NCCN) guidelines regarding the utilization of liquid and tissue biopsies, highlighting the necessity for the NCCN to prioritize and recommend concurrent testing as the preferred approach over relying on a single liquid or tissue biopsy alone.